Overview

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Status:
Completed

Trial end date:
2020-11-12

Target enrollment:

Participant gender:

Summary

This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Collaborators:

Alliance for Clinical Trials in Oncology
German Breast Group
Grupo Español de Investigación del Cáncer de Mama
NSABP Foundation Inc
US Oncology Research

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Paclitaxel
Veliparib